In the News: Sino-US Scientific Cooperation; AstraZeneca Splits Its China Operation?; and Italy Limits Influence of Chinese Company

June 21, 2023 | BY

Clarence Lee

The U.S. government is debating whether to renew the U.S.-China Science and Technology Agreement; AstraZeneca plans to break up its business in China and list it separately in Hong Kong; the Italian government applies Golden Power regulations to limit the influence of China's Sinochem on tyremaker Pirelli

Looker_Studio/Adobe Stock

Will a Scientific Cooperation Agreement Between the U.S. and China Come to an End?

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]